EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance

被引：30

作者：

Fogli, Stefano ^{[1
]}

Polini, Beatrice ^{[1
]}

Del Re, Marzia ^{[1
]}

Petrini, Iacopo ^{[2
]}

Passaro, Antonio ^{[3
]}

Crucitta, Stefania ^{[1
]}

Rofi, Eleonora ^{[1
]}

Danesi, Romano ^{[1
]}

机构：

[1] Univ Pisa, Dept Clin & Expt Med, Clin Pharmacol & Pharmacogenet Unit, Pisa, Italy

[2] Univ Pisa, Gen Pathol, Dept Translat Res & New Technol Surg & Med, Pisa, Italy

[3] European Inst Oncol, Div Thorac Oncol, Milan, Italy

来源：

PHARMACOGENOMICS | 2018年 / 19卷 / 08期

关键词：

drug resistance; EGFR TKIs; non-small-cell lung cancer; pharmacology; RECEPTOR TYROSINE KINASE; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; IRREVERSIBLE EGFR; T790M MUTATION; SURVIVAL-DATA; BIBW; 2992;

D O I：

10.2217/pgs-2018-0038

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.

引用

页码：727 / 740

页数：14

共 99 条

[51] Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors [J].

Nukaga, Shigenari ;

Yasuda, Hiroyuki ;

Tsuchihara, Katsuya ;

Hamamoto, Junko ;

Masuzawa, Keita ;

Kawada, Ichiro ;

Naoki, Katsuhiko ;

Matsumoto, Shingo ;

Mimaki, Sachiyo ;

Ikemura, Shinnosuke ;

Goto, Koichi ;

Betsuyaku, Tomoko ;

Soejima, Kenzo .

CANCER RESEARCH, 2017, 77 (08) :2078-2089

[52] Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations [J].

Oizumi, Satoshi ;

Sugawara, Shunichi ;

Minato, Koichi ;

Harada, Toshiyuki ;

Inoue, Akira ;

Fujita, Yuka ;

Maemondo, Makoto ;

Watanabe, Satoshi ;

Ito, Kazuhiko ;

Gemma, Akihiko ;

Demura, Yoshiki ;

Fukumoto, Shinichi ;

Isobe, Hiroshi ;

Kinoshita, Ichiro ;

Morita, Satoshi ;

Kobayashi, Kunihiko ;

Hagiwara, Koichi ;

Aiba, Keisuke ;

Nukiwa, Toshihiro .

ESMO OPEN, 2018, 3 (02)

[53] Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status [J].

Onitsuka, Takamitsu ;

Uramoto, Hidetaka ;

Nose, Naohiro ;

Takenoyama, Mitsuhiro ;

Hanagiri, Takeshi ;

Sugio, Kenji ;

Yasumoto, Kosei .

LUNG CANCER, 2010, 68 (02) :198-203

[54] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[55]

Park K, 2016, J THORAC ONCOL, V11, pS139, DOI 10.1016/S1556-0864(16)30299-4

[56] Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J].

Park, Keunchil ;

Tan, Eng-Huat ;

O'Byrne, Ken ;

Zhang, Li ;

Boyer, Michael ;

Mok, Tony ;

Hirsh, Vera ;

Yang, James Chih-Hsin ;

Lee, Ki Hyeong ;

Lu, Shun ;

Shi, Yuankai ;

Kim, Sang-We ;

Laskin, Janessa ;

Kim, Dong-Wan ;

Arvis, Catherine Dubos ;

Kolbeck, Arvis Karl ;

Laurie, Scott A. ;

Tsai, Chun-Ming ;

Shahidi, Mehdi ;

Kim, Miyoung ;

Massey, Dan ;

Zazulina, Victoria ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2016, 17 (05) :577-589

[57] Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment [J].

Passaro, Antonio ;

Guerini-Rocco, Elena ;

Pochesci, Alessia ;

Vacirca, Davide ;

Spitaleri, Gianluca ;

Catania, Chiara Matilde ;

Rappa, Alessandra ;

Barberis, Massimo ;

de Marinis, Filippo .

PHARMACOLOGICAL RESEARCH, 2017, 117 :406-415

[58] Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance [J].

Patel, Harun ;

Pawara, Rahul ;

Ansari, Azim ;

Surana, Sanjay .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 142 :32-47

[59] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [J].

Paz-Ares, L. ;

Tan, E. -H. ;

O'Byrne, K. ;

Zhang, L. ;

Hirsh, V. ;

Boyer, M. ;

Yang, J. C. -H. ;

Mok, T. ;

Lee, K. H. ;

Lu, S. ;

Shi, Y. ;

Lee, D. H. ;

Laskin, J. ;

Kim, D. -W. ;

Laurie, S. A. ;

Kolbeck, K. ;

Fan, J. ;

Dodd, N. ;

Marten, A. ;

Park, K. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :270-277

[60] Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions [J].

Peters, Solange ;

Zimmermann, Stefan ;

Adjei, Alex A. .

CANCER TREATMENT REVIEWS, 2014, 40 (08) :917-926

← 1 2 3 4 5 6 7 8 9 10 →